Search

Displaying results 3551 - 3560 of 10000 in total
  1. Target

    Dihydrolipoyl dehydrogenase

    go.drugbank.com/bio_entities/BE0002616
    TargetPseudomonas putida

    The branched-chain alpha-keto dehydrogenase complex catalyzes the overall conversion of alpha-keto acids to acyl-CoA and CO(2).

    Synonyms: E3 component of branched-chain alpha-keto acid dehydrogenase complex
  2. Drug

    Diethylpropion

    go.drugbank.com/drugs/DB00937
    ApprovedIllicitInvestigational

    It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290)

  3. Drug

    Aspartic acid

    go.drugbank.com/drugs/DB00128
    ApprovedInvestigationalNutraceutical

    It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.

    Synonyms: (S)-2-aminosuccinic acid, (S)-2-aminobutanedioic acid
  4. Drug

    Loncastuximab tesirine

    go.drugbank.com/drugs/DB16222
    ApprovedInvestigational

    [A234439] Prognosis is poor and more effective therapies are needed to treat relapsed/refractory cases and improve survival. … [A234444] On April 23 2021, the Food and Drug Administration granted accelerated approval for the antibody-drug conjugate, loncastuximab tesirine-lpyl, also known as Zynlonta.

  5. Drug

    Imelasomeran

    go.drugbank.com/drugs/DB17090
    ApprovedInvestigational

    Imelasomeran was first approved in Canada on September 1, 2022, as one-half of Moderna's Spikevax Bivalent COVID-19 mRNA vaccine.

  6. Drug

    Rilonacept

    go.drugbank.com/drugs/DB06372
    ApprovedInvestigational

    Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) … Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1.

  7. Drug

    Cenegermin

    go.drugbank.com/drugs/DB13926
    ApprovedInvestigational

    Cenegermin received approval from the US FDA a year later in August of 2018. [L4563] Neurotrophic keratitis is a degenerative disease resulting from a loss of corneal sensation. … The approval of cenegermin consequently provides a novel topical treatment that has the potential capacity to offer total corneal healing for many patients who may use the agent.

  8. Drug

    Enzalutamide

    go.drugbank.com/drugs/DB08899
    ApprovedInvestigational

    [A252667] Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide. … [L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant

  9. Drug

    Sparsentan

    go.drugbank.com/drugs/DB12548
    ApprovedInvestigational

    Furthermore, it is the first non-immunosuppressive therapy for the reduction of proteinuria in IgAN.[L45315] The use of sparsentan may cause hepatotoxicity and embryo-fetal toxicity. … [A257325,A257335,L45310] Compared to [irbesartan], sparsentan reduces proteinuria to a greater extent.

  10. Drug

    Nadofaragene firadenovec

    go.drugbank.com/drugs/DB17381
    ApprovedInvestigational

    Compared to [pembrolizumab], a smaller proportion of patients experienced grade 3-4 adverse events (4% vs 12.7%).[A255111] … It is the first gene therapy approved by the FDA for the treatment of bladder cancer.[L44381,L44431] BCG-unresponsive NMIBC has a high recurrence and is notably difficult to treat.

    Categories: Complex Mixtures